+1 (502) 904-2126   One Westbrook Corporate Center, Suite 300, Westchester, IL 60154, USA   Site Map
ISSN: 2574 -1241

Impact Factor : 0.548

  Submit Manuscript

Mini ReviewOpen Access

Aurora A and cancer

Volume 3 - Issue 4

Stephanie Le Bras, Arun Prasath Damodaran and Claude Prigent*

  • Author Information Open or Close
    • Rennes University, CNRS, IGDR Institute of Genetics and Development of Rennes, France

    *Corresponding author: Rennes University, CNRS, IGDR (Institute of Genetics and Development of Rennes), UMR 6290, Team labelled Cancer League 2014-2016, F-35000 Rennes, France

Received: February 21, 2018;   Published: April 06, 2018

DOI: 10.26717/BJSTR.2018.03.000922

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Aurora-A is a serine-threonine kinase found over expressed in cancers and demonstrated to be an oncogene. Since the kinase regulates cell cycle progression several pharmaceutical companies were involved in the identification of inhibitors to be used in cancer treatments. Many of such inhibitors are now commercially available but none of them succeeded any phase III clinical trials, yet. The concern here is, whether Aurora-A is still a good target or biomarker?

Abstract| Introduction| References|